PowerUp Acquisition Corp. (PWUP)
| Market Cap | 89.30M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.76M |
| Shares Out | 7.77M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,831 |
| Open | 11.50 |
| Previous Close | 11.50 |
| Day's Range | 11.50 - 11.50 |
| 52-Week Range | 10.88 - 14.47 |
| Beta | 0.02 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About PWUP
PowerUp Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on video gaming, gaming adjacent, and metaverse businesses. PowerUp Acquisition Corp. was incorporated in 2021 and is based in New York, New York. [Read more]
Financial Performance
Financial StatementsNews
Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements
Highlights Transaction Valuation: The transaction values Aspire Biopharma, Inc. at a pre-money equity value of approximately $316 million. Industry-Leading Platform: Aspire is focused on developing a ...
Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp.
Humacao, PR and New York, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of a multi-faceted patent protected disruptive drug delivery mechanism t...
PowerUp Acquisition Corp. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
New York, NY, June 05, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. (the “Company”) (Nasdaq: PWUP) announced today that, on June 3, 2024, the Company received a notice (the “Notice”) from the Na...
PowerUp Acquisition Corp. Announces Postponement of Extraordinary General Meeting of Shareholders
New York, NY, May 20, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. (the “Company”) (Nasdaq: PWUP) announced today that its extraordinary general meeting of shareholders (the “Meeting”), which wa...
PowerUp Acquisition Corp. and Visiox Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form S-4 to the SEC in Connection with the Previously Announced Proposed Business Combination
Tarrytown, NY and New York, NY, Jan. 29, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. (“PowerUp”) (Nasdaq: PWUP) and Visiox Pharmaceuticals, Inc. (“Visiox”), a commercial-stage biopharmaceutical...
Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.
Tarrytown, NY and New York, NY, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Visiox Pharmaceuticals, Inc. (“Visiox” or the “Company”), a commercial-stage biopharmaceutical company, and PowerUp Acquisition Corp. ...
PowerUp Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing April 11, 2022
NEW YORK--(BUSINESS WIRE)--PowerUp Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing April 11, 2022